Published in Medicine (Baltimore) on August 01, 2016
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Global epidemiology of hepatitis C virus infection. Lancet Infect Dis (2005) 16.44
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40
Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology (2013) 12.46
The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology (1998) 12.32
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (2006) 10.18
Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis (1999) 9.81
Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood (2004) 7.09
Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS (2003) 5.85
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology (1999) 5.55
Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet (2000) 5.49
Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med (2000) 4.98
Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol (2004) 3.99
Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int (2011) 3.36
The Th1-Th2 hypothesis of HIV infection: new insights. Immunol Today (1994) 3.01
Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology (2010) 2.44
Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol (2005) 2.27
Mechanisms of HIV-associated lymphocyte apoptosis. Blood (2000) 1.75
The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1. Blood (2004) 1.53
CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus. J Infect Dis (2008) 1.49
T cell responses in hepatitis C: the good, the bad and the unconventional. Gut (2011) 1.29
Assessing mortality in women with hepatitis C virus and HIV using indirect markers of fibrosis. AIDS (2012) 1.21
Coinfection with HIV and hepatitis C virus in injection drug users and minority populations. Clin Infect Dis (2005) 1.15
Hepatitis C infection in HIV-1 natural viral suppressors. AIDS (2010) 1.13
Hepatitis C and HIV co-infection: a review. World J Gastroenterol (2002) 1.12
Interferon-alpha administration enhances CD8+ T cell activation in HIV infection. PLoS One (2012) 1.06
Reduced naive CD4 T cell numbers and impaired induction of CD27 in response to T cell receptor stimulation reflect a state of immune activation in chronic hepatitis C virus infection. J Infect Dis (2011) 1.05
Effects of HCV co-infection on apoptosis of CD4+ T-cells in HIV-positive patients. Clin Sci (Lond) (2009) 0.99
Hepatitis C virus promotes T-helper (Th)17 responses through thymic stromal lymphopoietin production by infected hepatocytes. Hepatology (2013) 0.95
Coinfection with hepatitis C virus increases lymphocyte apoptosis in HIV-infected patients. Clin Infect Dis (2006) 0.94
Similar progression of fibrosis between HIV/HCV-infected and HCV-infected patients: Analysis of paired liver biopsy samples. Clin Gastroenterol Hepatol (2010) 0.90
Progression of biopsy-measured liver fibrosis in untreated patients with hepatitis C infection: non-Markov multistate model analysis. PLoS One (2011) 0.88
HCV coinfection does not alter the frequency of regulatory T cells or CD8+ T cell immune activation in chronically infected HIV+ Chinese subjects. AIDS Res Hum Retroviruses (2012) 0.87
Immune control and failure in HCV infection--tipping the balance. J Leukoc Biol (2014) 0.87
Influence of hepatitis C virus coinfection on CD4⁺ T cells of HIV-infected patients receiving HAART. AIDS (2014) 0.86
Characterization of CD4⁺ T-cell immune activation and interleukin 10 levels among HIV, hepatitis C virus, and HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr (2013) 0.84
Association of chronic hepatitis C infection with T-cell phenotypes in HIV-negative and HIV-positive women. J Acquir Immune Defic Syndr (2014) 0.80
Stable recovery from HCV in HIV-HCV co-infection under antiretroviral therapy. J Clin Virol (2007) 0.80
Case report: clearance of hepatitis C virus after changing the HAART regimen in a patient infected with hepatitis C virus and the human immunodeficiency virus. J Med Virol (2009) 0.79
Suppression of hepatitis C virus replication is maintained long term following HAART therapy, in an individual with HCV/HIV co-infection. Antivir Ther (2004) 0.77
Elevated caspase-3 expression and T-cell activation in elite suppressors. J Acquir Immune Defic Syndr (2010) 0.76
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75
Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med (2004) 7.67
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75
Soluble Urokinase Receptor and Chronic Kidney Disease. N Engl J Med (2015) 4.85
Competing risk regression models for epidemiologic data. Am J Epidemiol (2009) 4.75
Viral hepatitis in HIV infection. N Engl J Med (2007) 4.18
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS (2008) 3.66
Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis (2003) 3.63
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis (2007) 3.39
T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis (2011) 3.38
Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology (2013) 3.35
The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med (2004) 3.05
Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS (2003) 2.97
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology (2005) 2.91
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS (2008) 2.87
Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int (2002) 2.83
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr (2007) 2.73
The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood (2013) 2.72
C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med (2006) 2.67
Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clin Infect Dis (2007) 2.67
Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis (2004) 2.66
Vitamin D deficiency in HIV-infected and HIV-uninfected women in the United States. J Acquir Immune Defic Syndr (2011) 2.65
Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda. AIDS (2003) 2.60
Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis (2007) 2.55
Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy. Liver Transpl (2013) 2.53
IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood (2009) 2.50
Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo township, Qidong, People's Republic of China. Cancer Epidemiol Biomarkers Prev (2005) 2.45
Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS (2005) 2.42
Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol (2002) 2.32
Driving status and risk of entry into long-term care in older adults. Am J Public Health (2006) 2.32
Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst (2004) 2.23
Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr (2004) 2.21
Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the women's interagency HIV study. Am J Public Health (2006) 2.19
U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med (2012) 2.18
Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol (2004) 2.17
Cytomegalovirus immunoglobulin G antibody is associated with subclinical carotid artery disease among HIV-infected women. J Infect Dis (2012) 2.16
Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 2.11
Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med (2002) 2.11
HIV-1 target cells in foreskins of African men with varying histories of sexually transmitted infections. Am J Clin Pathol (2006) 2.10
Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis (2009) 2.05
Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols. AIDS (2005) 2.03
Marginal and mixed-effects models in the analysis of human papillomavirus natural history data. Cancer Epidemiol Biomarkers Prev (2010) 2.00
Comparison of the diversity of the vaginal microbiota in HIV-infected and HIV-uninfected women with or without bacterial vaginosis. J Infect Dis (2008) 1.99
The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr (2005) 1.96
Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. J Infect Dis (2009) 1.95
Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV Study. Clin Infect Dis (2004) 1.94
The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women. AIDS (2011) 1.94
Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis (2013) 1.94
Increase in sexual risk behavior associated with immunologic response to highly active antiretroviral therapy among HIV-infected injection drug users. Clin Infect Dis (2004) 1.89
Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS (2010) 1.83
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
Role of alphavbeta6 integrin in acute biliary fibrosis. Hepatology (2007) 1.80
Virological and immunological characteristics of human cytomegalovirus infection associated with Alzheimer disease. J Infect Dis (2013) 1.80
Factors associated with use of dental services among HIV-infected and high-risk uninfected women. J Am Dent Assoc (2005) 1.79
Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr (2003) 1.78
Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease. Arch Intern Med (2002) 1.75
Retention among North American HIV-infected persons in clinical care, 2000-2008. J Acquir Immune Defic Syndr (2013) 1.73
Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr (2013) 1.72
Does patient sex affect human immunodeficiency virus levels? Clin Infect Dis (2002) 1.72
Aging is associated with chronic innate immune activation and dysregulation of monocyte phenotype and function. Aging Cell (2012) 1.71
Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis (2011) 1.70
Protease inhibitor levels in hair strongly predict virologic response to treatment. AIDS (2009) 1.68
Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-1-infected women receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2004) 1.66
T cell activation predicts carotid artery stiffness among HIV-infected women. Atherosclerosis (2011) 1.64
Mortality among a cohort of drug users after their release from prison: an evaluation of the effectiveness of a harm reduction program in Taiwan. Addiction (2011) 1.64
The parametric g-formula to estimate the effect of highly active antiretroviral therapy on incident AIDS or death. Stat Med (2012) 1.63
Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11. Immunology (2007) 1.63
Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy. AIDS Res Hum Retroviruses (2007) 1.63
Multisite comparison of high-sensitivity multiplex cytokine assays. Clin Vaccine Immunol (2011) 1.62
Interval and clinical cohort studies: epidemiological issues. AIDS Res Hum Retroviruses (2007) 1.61
Prevalence and predictors of Toxoplasma seropositivity in women with and at risk for human immunodeficiency virus infection. Clin Infect Dis (2002) 1.59
Changes in sexual behavior among HIV-infected women after initiation of HAART. Am J Public Health (2004) 1.59
Effectiveness of highly-active antiretroviral therapy by race/ethnicity. AIDS (2006) 1.55
HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy. AIDS (2012) 1.55
The effect of aging on T-regulatory cell frequency in HIV infection. Clin Immunol (2008) 1.55
Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl (2014) 1.54
The association of serum ferritin and transferrin receptor concentrations with mortality in women with human immunodeficiency virus infection. Haematologica (2006) 1.53
Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res (2004) 1.50